Teva Pharma Industries Stock EBITDA
| TEVA Stock | USD 16.59 0.10 0.60% |
Teva Pharma Industries fundamentals help investors to digest information that contributes to Teva Pharma's financial success or failures. It also enables traders to predict the movement of Teva Stock. The fundamental analysis module provides a way to measure Teva Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharma stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 433 M | 411.4 M |
Teva | EBITDA |
Teva Pharma Industries Company EBITDA Analysis
Teva Pharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Teva Pharma EBITDA | 433 M |
Most of Teva Pharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharma Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Teva EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Teva Pharma is extremely important. It helps to project a fair market value of Teva Stock properly, considering its historical fundamentals such as EBITDA. Since Teva Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Teva Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Teva Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Teva Ebitda
Ebitda |
|
According to the company disclosure, Teva Pharma Industries reported earnings before interest,tax, depreciation and amortization of 433 M. This is 50.65% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 88.89% higher than that of the company.
Teva EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Teva Pharma could also be used in its relative valuation, which is a method of valuing Teva Pharma by comparing valuation metrics of similar companies.Teva Pharma is currently under evaluation in ebitda category among its peers.
Teva Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Teva Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Teva Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Teva Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Teva Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Teva Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Teva Pharma's value.| Shares | Slate Path Capital Lp | 2024-09-30 | 13.7 M | Millennium Management Llc | 2024-06-30 | 12.1 M | Pointstate Capital Lp | 2024-09-30 | 9.8 M | Geode Capital Management, Llc | 2024-09-30 | 8.8 M | Glenview Capital Management Llc | 2024-09-30 | 8.5 M | Renaissance Technologies Corp | 2024-09-30 | 8.1 M | Australiansuper Pty Ltd | 2024-09-30 | 7.9 M | Viking Global Investors Lp | 2024-09-30 | 7.6 M | Parsifal Capital Management, Lp | 2024-09-30 | 6.2 M | Fmr Inc | 2024-09-30 | 62.7 M | Blackrock Inc | 2024-06-30 | 43 M |
Teva Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | 0.0556 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 34.85 B | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Institutions | 57.23 % | ||||
| Number Of Shares Shorted | 18.09 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.12 X | ||||
| Price To Sales | 1.13 X | ||||
| Revenue | 15.85 B | ||||
| Gross Profit | 6.97 B | ||||
| EBITDA | 433 M | ||||
| Net Income | (615 M) | ||||
| Cash And Equivalents | 2.22 B | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 20.15 B | ||||
| Debt To Equity | 2.27 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 5.35 X | ||||
| Cash Flow From Operations | 1.37 B | ||||
| Short Ratio | 3.50 X | ||||
| Earnings Per Share | (0.85) X | ||||
| Price To Earnings To Growth | 1.29 X | ||||
| Target Price | 22.36 | ||||
| Number Of Employees | 37 K | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 18.91 B | ||||
| Total Asset | 43.48 B | ||||
| Retained Earnings | (13.53 B) | ||||
| Working Capital | 238 M | ||||
| Current Asset | 18.4 B | ||||
| Current Liabilities | 13.01 B | ||||
| Five Year Return | 2.95 % | ||||
| Net Asset | 43.48 B |
About Teva Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharma Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharma Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out Teva Pharma Piotroski F Score and Teva Pharma Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.